IDYA
Income statement / Annual
Last year (2025), Ideaya Biosciences Inc's total revenue was $218.71 M,
an increase of 3,024.43% from the previous year.
In 2025, Ideaya Biosciences Inc's net income was -$113.70 M.
See Ideaya Biosciences Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$218.71 M |
$7.00 M |
$23.39 M |
$50.93 M |
$27.94 M |
$19.54 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$4.59 M
|
$3.83 M
|
$4.01 M
|
$2.10 M
|
$1.73 M
|
$1.38 M
|
$1.25 M
|
$886.00 K
|
$391.00 K
|
| Gross Profit |
$214.12 M
|
$3.17 M
|
$19.38 M
|
$48.83 M
|
$26.22 M
|
$18.16 M
|
-$1.25 M
|
-$886.00 K
|
-$391.00 K
|
| Gross Profit Ratio |
0.98
|
0.45
|
0.83
|
0.96
|
0.94
|
0.93
|
0
|
0
|
0
|
| Research and Development Expenses |
$314.70 M
|
$294.67 M
|
$129.51 M
|
$89.54 M
|
$58.16 M
|
$39.70 M
|
$34.32 M
|
$31.75 M
|
$12.38 M
|
| General & Administrative Expenses |
$63.32 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$63.32 M
|
$35.47 M
|
$24.30 M
|
$21.80 M
|
$18.33 M
|
$13.80 M
|
$8.71 M
|
$3.78 M
|
$1.66 M
|
| Other Expenses |
-$4.59 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$373.43 M
|
$330.14 M
|
$153.81 M
|
$111.33 M
|
$76.48 M
|
$53.50 M
|
$43.03 M
|
$35.53 M
|
$14.05 M
|
| Cost And Expenses |
$378.02 M
|
$333.98 M
|
$157.81 M
|
$113.43 M
|
$78.21 M
|
$54.88 M
|
$44.27 M
|
$36.42 M
|
$14.44 M
|
| Interest Income |
$45.62 M
|
$52.50 M
|
$21.47 M
|
$3.85 M
|
$506.00 K
|
$849.00 K
|
$2.29 M
|
$1.99 M
|
$150.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$4.59 M
|
$3.83 M
|
$4.01 M
|
$2.10 M
|
$1.73 M
|
$1.38 M
|
$1.25 M
|
$886.00 K
|
$391.00 K
|
| EBITDA |
-$154.72 M |
-$270.64 M |
-$108.95 M |
-$56.55 M |
-$48.04 M |
-$33.11 M |
-$40.73 M |
-$33.46 M |
-$11.47 M |
| EBITDA Ratio |
-0.71
|
-38.66
|
-4.66
|
-1.11
|
-1.72
|
-1.69
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.73
|
-46.71
|
-5.75
|
-1.23
|
-1.8
|
-1.81
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$45.62 M
|
$52.50 M
|
$21.47 M
|
$3.85 M
|
$506.00 K
|
$849.00 K
|
$2.30 M
|
$2.07 M
|
$2.58 M
|
| Income Before Tax |
-$113.70 M
|
-$274.48 M
|
-$112.96 M
|
-$58.66 M
|
-$49.76 M
|
-$34.50 M
|
-$41.98 M
|
-$34.35 M
|
-$11.86 M
|
| Income Before Tax Ratio |
-0.52
|
-39.21
|
-4.83
|
-1.15
|
-1.78
|
-1.77
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$113.70 M
|
-$274.48 M
|
-$112.96 M
|
-$58.66 M
|
-$49.76 M
|
-$34.50 M
|
-$41.98 M
|
-$34.35 M
|
-$11.86 M
|
| Net Income Ratio |
-0.52
|
-39.21
|
-4.83
|
-1.15
|
-1.78
|
-1.77
|
0
|
0
|
0
|
| EPS |
-1.28 |
-3.36 |
-1.96 |
-1.42 |
-1.41 |
-1.31 |
-1.9 |
-2.41 |
-0.83 |
| EPS Diluted |
-1.28 |
-3.36 |
-1.96 |
-1.42 |
-1.41 |
-1.31 |
-1.9 |
-2.41 |
-0.83 |
| Weighted Average Shares Out |
$88.49 M
|
$81.68 M
|
$57.52 M
|
$41.44 M
|
$35.25 M
|
$24.72 M
|
$20.23 M
|
$14.24 M
|
$14.24 M
|
| Weighted Average Shares Out Diluted |
$88.49 M
|
$81.68 M
|
$57.52 M
|
$41.44 M
|
$35.25 M
|
$24.72 M
|
$20.23 M
|
$14.24 M
|
$14.24 M
|
| Link |
|
|
|
|
|
|
|
|
|
